Oramed Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Oramed Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Oramed Pharmaceuticals Inc Strategy Report
- Understand Oramed Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Oramed Pharmaceuticals Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
18 Mar 2024 | Oramed Pharma to Raise Up to USD75 Million in Public Offering of Common Stock | Equity Offering | - |
Oramed Pharmaceuticals Inc |
02 Aug 2023 | Oramed Pharma to Form Joint Venture with Hefei Tianhui Biotech | Partnership | - |
Hefei Tianhui Biotechnology Co Ltd
Oramed Pharmaceuticals Inc |
01 May 2023 | Ben Shapiro Acquires 4.8% Stake in Oramed Pharmaceuticals for USD4.7 Million | Acquisition |
Ben Shapiro
|
Oramed Ltd
|
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer